<DOC>
	<DOCNO>NCT00055705</DOCNO>
	<brief_summary>RATIONALE : PV701 may able kill tumor cell leave normal cell undamaged . PURPOSE : Phase I trial study effectiveness PV701 treat patient advanced recurrent ovarian epithelial , fallopian tube , primary peritoneal , colorectal , cancer find primarily within peritoneal cavity .</brief_summary>
	<brief_title>PV701 Treating Patients With Advanced Recurrent Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity maximum tolerate dose intraperitoneal PV701 desensitization patient advance recurrent malignancy largely confine peritoneal cavity patient . - Determine optimal desensitization dose intravenous PV701 patient . - Determine safety drug , term cumulative toxicity , patient . - Determine , preliminarily , antitumor activity drug patient . - Determine presence duration viral shedding , viremia , immunogenicity drug . OUTLINE : This open-label , dose-escalation study comprise 2 different treatment schedule . - Schedule I ( optimal desensitization dose ) : Patients receive PV701 IV 30 minute day 1 follow intraperitoneal ( IP ) PV701 day 4 , 7 , 9 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PV701 IV IP optimal desensitization dose ( ODD ) determine . The ODD define dose precede least 2 6 patient experience dose-limiting toxicity ( DLT ) . - Schedule II ( maximum tolerate dose ) : Patients receive regimen schedule I use PV701 IV ODD . Cohorts 3-6 patient receive escalate dos PV701 IP maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience DLT . PROJECTED ACCRUAL : A total 3-50 patient accrue study within 10-17 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histological confirmation 1 following : Ovarian epithelial carcinoma Fallopian tube cancer Primary peritoneal cancer Advanced colorectal carcinoma Other malignancy confine peritoneal cavity peritoneal surface No lesion great 2 cm great diameter base surgical reassessment Low burden tumor abdominal pelvic cavity clinically significant ascites Received potentially effective therapy available ( e.g. , platinum/taxane ovarian cancer , fluoropyrimidinebased therapy colorectal cancer ) No concurrent hematological malignancy ( e.g. , chronic lymphocytic leukemia nonHodgkin 's lymphoma ) No bilateral adrenal metastases No adrenal metastasis remain adrenal gland adrenalectomy ( include radical nephrectomy ) No lung tumor 5 cm No pleural effusion ( least 25 % hemithorax ) radiography No CNS metastases CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 9 g/dL Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 1.5 time ULN Alkaline phosphatase great 1.5 time ULN No uncontrolled hepatic dysfunction No active hepatitis B C Renal See Disease Characteristics Creatinine great 1.6 mg/dL AND/OR Creatinine clearance least 50 mL/min No uncontrolled renal dysfunction Cardiovascular No uncontrolled cardiovascular dysfunction No myocardial infarction within past 6 month No lifethreatening arrhythmias within past 6 month Pulmonary See Disease Characteristics No uncontrolled pulmonary dysfunction No pulmonary atelectasis ( lobar ) No pulmonary infiltrates ( lobar ) No pulmonary consolidation ( lobar segmental ) No baseline grade II dyspnea Adrenal See Disease Characteristics No uncontrolled adrenal dysfunction No known adrenal insufficiency Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled gastrointestinal dysfunction No neurological dysfunction No serious medical psychological condition would preclude study participation increase risk adverse effect study treatment No history serious immunodeficiency No active uncontrolled bacterial infection ( include asymptomatic urinary tract infection ) No contraindication intraperitoneal therapy include follow : Intraabdominal infection Dense widespread adhesion Peritonitis Periumbilical infection Bowel obstruction Ileostomy No hypersensitivity egg No continued contact live bird ( e.g. , poultry farmer , veterinarian , laboratory technician , pet store owner , breeder ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No 3 prior cytotoxic chemotherapy regimens More 30 day since prior chemotherapy Endocrine therapy More 14 day since prior systemic corticosteroid Radiotherapy More 30 day since prior radiotherapy Surgery See Disease Characteristics No prior complete partial lobectomy removal lung tissue least segmental size No prior organ allograft Other Recovered prior therapy More 14 day since prior antiviral medication More 4 week since prior immunosuppressive drug No concurrent investigational drug No concurrent chronic immunosuppressive drug ( e.g. , cyclosporine ) No vaccination influenza within 48 hour study drug administration No concurrent hypoglycemic agent No concurrent antiretroviral therapy HIVpositive patient No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>